Abstract

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment.

Author affiliations

1. Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin, Berlin, Campus Virchow, Klinikum, 13353 Berlin, Germany.
2. Vesalius Research Center, Flanders Institute for Biotechnology (VIB), Leuven, B-3000, Belgium.
3. Vesalius Research Center, Campus Gasthuisberg, Katholieke Universiteit Leuven, Herestraat 49, Leuven, B-3000, Belgium.

Correspondence to: Peter Carmeliet^2,3 Email: peter.carmeliet@med.kuleuven.be

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.